| Literature DB >> 35214871 |
Sabrin R M Ibrahim1,2, Abdelsattar M Omar3,4,5, Alaa A Bagalagel6, Reem M Diri6, Ahmad O Noor6, Diena M Almasri6, Shaimaa G A Mohamed7, Gamal A Mohamed8.
Abstract
Naturally, thiophenes represent a small family of natural metabolites featured by one to five thiophene rings. Numerous plant species belonging to the family Asteraceae commonly produce thiophenes. These metabolites possessed remarkable bioactivities, including antimicrobial, antiviral, anti-inflammatory, larvicidal, antioxidant, insecticidal, cytotoxic, and nematicidal properties. The current review provides an update over the past seven years for the reported natural thiophene derivatives, including their sources, biosynthesis, spectral data, and bioactivities since the last review published in 2015. Additionally, with the help of the SuperPred webserver, an AI (artificial intelligence) tool, the potential drug target for the compounds was predicted. In silico studies were conducted for Cathepsin D with thiophene derivatives, including ADMET (drug absorption/distribution/metabolism/excretion/and toxicity) properties prediction, molecular docking for the binding interaction, and molecular dynamics to evaluate the ligand-target interaction stability under simulated physiological conditions.Entities:
Keywords: Asteraceae; bioactivities; biosynthesis; cathepsin D; in silico studies; spectral data; thiophenes
Year: 2022 PMID: 35214871 PMCID: PMC8877444 DOI: 10.3390/plants11040539
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1Number of reported thiophenes from various sources.
Figure 2Biological activities of thiophenes.
Naturally occurring mono-, bi-, ter-, and quinquethiophenes and miscellaneous derivatives (name, source, molecular weights and formulae, and location).
| Compound Name | Source | Extract/Fraction | Mol. Wt. | Mol. Formula | Location | Ref. |
|---|---|---|---|---|---|---|
| I. Monothiophenes | ||||||
| Foetithiophene A ( | MeOH/EtOAc-soluble fraction | 170 | C8H10O2S | Dorouneh village mountains, Khorasan Razavi, Iran | [ | |
| Foetithiophene B ( | MeOH/EtOAc-soluble fraction | 218 | C9H14O2S2 | Dorouneh village mountains, Khorasan Razavi, Iran | [ | |
| Foetithiophene C ( | MeOH/EtOAc-soluble fraction | 186 | C9H14S2 | Dorouneh village mountains, Khorasan Razavi, Iran | [ | |
| Foetithiophene D ( | MeOH/EtOAc-soluble fraction | 310 | C16H22S3 | Dorouneh village mountains, Khorasan Razavi, Iran | [ | |
| Foetithiophene E ( | MeOH/EtOAc-soluble fraction | 202 | C9H14OS2 | Dorouneh village mountains, Khorasan Razavi, Iran | [ | |
| Foetithiophene F ( | MeOH/EtOAc-soluble fraction | 188 | C9H16S2 | Dorouneh village mountains, Khorasan Razavi, Iran | [ | |
| 5-Propinyl-thiophene-2-Carboxylic acid = Junipic acid ( | EtOH/CH3Cl-soluble fraction | 166 | C8H6O2S | Qinghai, China | [ | |
| EtOH/EtOAc-soluble fraction | - | - | Qinghe County, Xinjiang, China | [ | ||
| 3-Hydroxy-5-propinyl-2-acetyl-thiophene ( | EtOH/CH3Cl-soluble fraction | 180 | C9H8O2S | Qinghai, China | [ | |
| 2-(3,4-Dihydroxybut-1-ynyl)-5-(penta-1,3-diynyl)thiophene = 2-(Penta-1,3-diynyl)-5-(3,4-dihydroxybut-1-ynyl)-thiophene = | MeOH/EtOAc-soluble fraction | 230 | C13H10O2S | Nantou, Taiwan | [ | |
| MeOH/CH2Cl2-soluble fraction | - | - | Dschang, Western Region of Cameroon | [ | ||
| MeOH/ | - | - | Dschang, Western Region of Cameroon | [ | ||
| EtOH/EtOAc-soluble fraction | - | - | Qinghe County, Xinjiang, China | [ | ||
| 2-(4-Hydroxybut-1-ynyl)-5-(penta-1,3-diynyl)thiophene ( | MeOH/EtOAc-soluble fraction | 214 | C13H10OS | Nantou, Taiwan | [ | |
| 2-(Penta-1,3-diyn-1-yl)-5–(4-acetoxy-3-hydroxybuta-1-yn-1-yl) thiophene ( | EtOH/ | 256 | C15H12O2S | Bon subdistrict, Khlung, Chantaburi, Thailand | [ | |
| 5-(Penta-1,3-diynyl)-2-(3-hydroxy-4-acetoxybut-1-ynyl)-thiophene ( | MeOH/CH2Cl2-soluble fraction | 272 | C15H12O3S | Bale Mountains National Park, Ethiopia | [ | |
| 5-(Penta-1,3-diynyl)-2-(3-methoxy-4-acetoxy-but-1-yn)-thiophene ( | MeOH/CH2Cl2-soluble fraction | 286 | C16H14O3S | Bale Mountains National Park, Ethiopia | [ | |
| 5-(Penta-1,3-diynyl)-2-(3-chloro-4-acetoxy-but-1-yn)-thiophene ( | MeOH/CH2Cl2-soluble fraction | 290 | C15H11ClO2S | Bale Mountains National Park, Ethiopia | [ | |
| Echinothiophene A ( | EtOH/CH2Cl2-soluble fraction | 248 | C13H9ClOS | Zhangjiakou Hebei, China | [ | |
| Echinothiophene B ( | EtOH/CH2Cl2-soluble fraction | 290 | C15H11ClO2S | Zhangjiakou Hebei, China | [ | |
| Echinothiophene C ( | EtOH/CH2Cl2-soluble fraction | 398 | C23H26O4S | Zhangjiakou Hebei, China | [ | |
| 2-(Pro-1-ynyl)-5-(5,6-dihydroxypenta-1,3-diynyl) thiophene (PYDDT) = 2-(Prop-1-ynyl)-5(5,6-dihydroxyhexa-1, 3-diynyl)-thiophene = PITC-2 = R/J/3 ( | EtOH/CH2Cl2-soluble fraction | 230 | C13H10O2S | Bozhou north of Anhui, China | [ | |
| EtOH/ | - | - | Bon subdistrict, Khlung, Chantaburi, Thailand | [ | ||
| 5-(1,2-Dihydroxyethyl)-2-( | MeOH/CH2Cl2-soluble fraction | 232 | C13H12O2S | Seoul, Korea | [ | |
| 5-(1,2-Dihydroxy-ethyl)-2-( | MeOH/CH2Cl2-soluble fraction | 232 | C13H12O2S | Seoul, Korea | [ | |
| 5-(Penta-1,3-diynyl)-2-(3-methoxy-4-hydroxybut-1-ynyl)-thiophen ( | MeOH/CH2Cl2-soluble fraction | 244 | C14H12O2S | Bale Mountains National Park, | [ | |
| 2-(Prop-1-inyl)-5-(6-acetoxy-5-hydroxyhexa-1,3-diinyl) thiophene ( | EtOH/ | 256 | C15H12O2S | Bon subdistrict, Khlung, Chantaburi, Thailand | [ | |
| 53′′ | EtOH/ | 230 | C13H10O2S | Hepu, Guangxi, China | [ | |
| 3′′ | EtOH/ | 272 | C15H12O3S | Hepu, Guangxi, China | [ | |
| 3′′-Ethoxy-3′′ | EtOH/ | 258 | C15H14O2S | Hepu, Guangxi, China | [ | |
| 3′′-Ethoxy-3′′ | EtOH/ | 300 | C17H16O3S | Hepu, Guangxi, China | [ | |
| Rupestriene B ( | EtOH/CH3Cl-soluble fraction | 234 | C13H14O2S | Xinjiang Uygur Autonomous, | [ | |
| Rupestriene C ( | EtOH/CH3Cl-soluble fraction | 234 | C13H14O2S | Xinjiang Uygur Autonomous, | [ | |
| Atracthioenyneside A ( | EtOH/n-BuOH extract | 414 | C19H26O8S | Huanggang, Hubei, China | [ | |
| Atracthioenyneside B ( | EtOH/n-BuOH extract | 386 | C17H22O8S | Huanggang, Hubei, China | [ | |
| ( | EtOH/PE-soluble fraction | 232 | C13H12O2S | Mount Kunyu area, Shandong, China | [ | |
| II. Bithiophenes | ||||||
| 5-(4-Hydroxy-3-methoxy-1-butyny)-2,2′-bithiophene ( | MeOH/EtOAc-soluble fraction | 264 | C13H12O2S2 | Nantou, Taiwan | [ | |
| 5-(3,4-Dihydroxybut-1-ynyl)-2,2′-bithiophene = | MeOH/EtOAc-soluble fraction | 250 | C12H10O2S2 | Nantou, Taiwan | [ | |
| MeOH/EtOAc-soluble fraction | - | - | Seoul, Korea | [ | ||
| EtOH/EtOAc-soluble fraction | - | - | Qinghe County, Xinjiang, China | [ | ||
| 5-Acetyl-2,2′-bithiophene | MeOH/EtOAc-soluble fraction | 208 | C10H8OS2 | Nantou, Taiwan | [ | |
| EtOH/EtOAc-soluble fraction | - | - | Qinghe County, Xinjiang, China | [ | ||
| 5-Formyl-2,2′-bithiophene ( | MeOH/EtOAc-soluble fraction | 194 | C9H6OS2 | Nantou, Taiwan | [ | |
| Methyl 2,2′-bithiophene-5-carboxylate ( | MeOH/EtOAc-soluble fraction | 224 | C10H8O2S2 | Nantou, Taiwan | [ | |
| 5-(But-3-en-1-ynyl)-2,2′-bithiophene (5-BBT) ( | MeOH/EtOAc-soluble fraction | 216 | C12H8S2 | Nantou, Taiwan | [ | |
| - | - | Las Chacras, province of San Luis, Argentina | [ | |||
| Essential oil, hydrodistillation | - | - | Nanjing, Jiangsu, China | [ | ||
| MeOH/CH2Cl2 soluble fraction | - | - | Malaysary gorge, Kazakhstan | [ | ||
| 5-(4-Isovaleroyloxybut-1-ynyl)-2,2′-bithiophene (5-IBT) ( | MeOH/EtOAc-soluble fraction | 318 | C17H18O2S2 | Nantou, Taiwan | [ | |
| Essential oil, hydrodistillation | - | - | Nanjing, Jiangsu, China | [ | ||
| Cardopatine ( | MeOH/EtOAc-soluble fraction | 432 | C24H16S4 | Nantou, Taiwan | [ | |
| Isocardopatine ( | MeOH/EtOAc-soluble fraction | 432 | C24H16S4 | Nantou, Taiwan | [ | |
| 5-(3-Hydroxy-4-isovaleroyloxybut-1-ynyl)-2,2′-bithiophene ( | MeOH/EtOAc-soluble fraction | 334 | C17H18O3S2 | Nantou, Taiwan | [ | |
| 5-(3-Hydroxymethyl-3-isovaleroyloxyprop-1-ynyl)-2,2′-bithiophene ( | MeOH/EtOAc-soluble fraction | 334 | C17H18O3S2 | Nantou, Taiwan | [ | |
| 5-(4-Hydroxy-1-butynyl)-2,2′-bithiophene | MeOH/EtOAc-soluble fraction | 234 | C12H10OS2 | Nantou, Taiwan | [ | |
| - | - | Las Chacras, province of San Luis, Argentina | [ | |||
| EtOH/EtOAc-soluble fraction | - | - | Qinghe County, Xinjiang, China | [ | ||
| MeOH/ | - | - | Al-Baha city, Saudi Arabia | [ | ||
| 5-(4-Acetoxy-1-butynl)-2,2′-bithiophene ( | MeOH/EtOAc-soluble fraction | Nantou, Taiwan | [ | |||
| - | - | Las Chacras, province of San Luis, Argentina | [ | |||
| 2,2′-Bithiophene-5-carboxylic acid ( | MeOH/EtOAc-soluble fraction | 209 | C9H6O2S2 | Nantou, Taiwan | [ | |
| EtOH/EtOAc-soluble fraction | - | - | Qinghe County, Xinjiang, China | [ | ||
| Thiotagetin B: [( | MeOH/ | 388 | C21H21ClOS5 | Al-Baha city, Saudi Arabia | [ | |
| 1-([2,2′-Bithiophen]-5-yl)-4 -hydroxybutan-1-one ( | EtOH/EtOAc-soluble fraction | 252 | C12H12O2S2 | Qinghe County, Xinjiang, China | [ | |
| 6-Methoxy-arctinol-b ( | MeOH/CH2Cl2-soluble fraction | 278 | C14H14O2S2 | Seoul, Korea | [ | |
| Arctinol-b ( | MeOH/CH2Cl2-soluble fraction | 264 | C13H12O2S2 | Seoul, Korea | [ | |
| EtOH/EtOAc-soluble fraction | - | - | Qinghe County, Xinjiang, China | [ | ||
| Arctinone-b ( | EtOH/CH2Cl2-soluble fraction | 246 | C13H10OS2 | Zhangjiakou Hebei, China | [ | |
| Arctinol ( | Echinops latifolius, roots (Asteraceae) | MeOH/CH2Cl2-soluble fraction | 248 | C12H8O2S2 | Seoul, Korea | [ |
| Arctinal ( | EtOH/EtOAc-soluble fraction | 232 | C12H8OS2 | Qinghe County, Xinjiang, China | [ | |
| Arctinol A ( | EtOH/EtOAc-soluble fraction | 234 | C12H10OS2 | Qinghe County, Xinjiang, China | [ | |
| Arctic acid ( | EtOH/EtOAc-soluble fraction | 248 | C12H8O2S2 | Qinghe County, Xinjiang, China | [ | |
| Methyl [5′-(1-propynyf)-2,2′-bithienyl-5-yl] carboxylate ( | MeOH/CH2Cl2-soluble fraction | 262 | C13H10O2S2 | Seoul, Korea | [ | |
| 2,2-Dimethyl-4-[5′-(prop-1-ynyl)-2,2′-bithiophen-5-yl]-1,3-dioxolane ( | EtOH/CH2Cl2-soluble fraction | 304 | C16H16O2S2 | Morocco | [ | |
| 5′-(3,4-Dihydroxybut-1-yn-1-yl)-[2,2′-bithiophene]-5-carbaldehyde = 5-[l-(4-hydroxybut-l-ynyl)]-2,2′-bithiophene-5′-carbaldehyde ( | EtOH/EtOAc-soluble fraction | 278 | C13H10O3S2 | Qinghe County, Xinjiang, China | [ | |
| 4-Hydroxy-1-(5′-methyl-[2,2′-bithiophen]-5-yl)butan-1-one ( | EtOH/EtOAc-soluble fraction | 266 | C13H14O2S2 | Qinghe County, Xinjiang, China | [ | |
| 5′-(3,4-Dihydroxybut-1-yn-1-yl)-[2,2′-bithiophene]-5-carboxylic acid ( | EtOH/EtOAc-soluble fraction | 294 | C13H10O4S2 | Qinghe County, Xinjiang, China | [ | |
| 4-(5′-Methyl-[2,2′-bithiophen]-5-yl)but-3-yn-1-ol ( | EtOH/EtOAc-soluble fraction | 248 | C13H12OS2 | Qinghe County, Xinjiang, China | [ | |
| Echinothiophene D ( | EtOH/CH2Cl2-soluble fraction | 298 | C13H14O4S2 | Zhangjiakou Hebei, China | [ | |
| Echinothiophene E ( | EtOH/CH2Cl2-soluble fraction | 366 | C18H19ClO2S2 | Zhangjiakou Hebei, China | [ | |
| Echinothiophene F ( | EtOH/CH2Cl2-soluble fraction | 432 | C23H28O4S2 | Zhangjiakou Hebei, China | [ | |
| 2-Prop-1-inyl-5′-(2-hydroxy-3-chloropropyl) dithiophene ( | EtOH/CH2Cl2-soluble fraction | 282 | C13H11ClOS2 | Zhangjiakou Hebei, China | [ | |
| Ecliprostin A ( | EtOH/EtOAc-soluble fraction | 348 | C18H20O3S2 | Mount Kunyu area, Shandong, China | [ | |
| Ecliprostin B ( | EtOH/EtOAc-soluble fraction | 348 | C18H20O3S2 | Mount Kunyu area, Shandong, China, | [ | |
| Ecliprostin C ( | EtOH/EtOAc-soluble fraction | 678 | C36H38O5S4 | Mount Kunyu area, Shandong, China | [ | |
| Echinbithiophenedimer A ( | EtOH/ | 492 | C26H20O2S4 | Mentougou, Beijing, China | [ | |
| Echinbithiophenedimer B ( | EtOH/ | 492 | C26H20O2S4 | Mentougou, Beijing, China | [ | |
| Echinbithiophenedimer C ( | EtOH/ | 492 | C26H20O2S4 | Mentougou, Beijing, China | [ | |
| ( | EtOH/PE-soluble fraction | 364 | C18H20O4S2 | Mount Kunyu area, Shandong, China | [ | |
| 5-[l-(4-hydroxybut-l-ynyl)]-2,2′-bithiophene-5′-carbaldehyde ( | EtOH/PE-soluble fraction | 262 | C13H10O2S2 | Mount Kunyu area, Shandong, China | [ | |
| 5′-Hydroxymethyl-5-(3-butene-1-ynyl)-2,2′-bithiophene ( | EtOH/PE-soluble fraction | 246 | C13H10OS2 | Mount Kunyu area, Shandong, China | [ | |
| 4-(5′-(hydroxymethyl)-[2,2′-bithiophene]-5-yl)but-3-yn-1-ol) (Thio1) ( | Synthesis | 264 | C13H12O2S2 | - | [ | |
| III. Terthiophene | ||||||
| 2,2′:5′,2′′-Terthiophene (α-Terthienyl) (α-T) ( | MeOH/EtOAc-soluble fraction | 248 | C12H8S3 | Nantou, Taiwan | [ | |
| MeOH/EtOAc-soluble fraction | - | - | Seoul, Korea | [ | ||
| - | - | Las Chacras, province of San Luis, Argentina | [ | |||
| Essential oil, hydrodistillation | - | - | Nanjing, Jiangsu, China | [ | ||
| MeOH/CH2Cl2 soluble fraction | - | - | Malaysary gorge, Kazakhstan | [ | ||
| 5-Formyl-2,2′:5′,2′′-terthiophene (Ecliptal) ( | MeOH/EtOAc-soluble fraction | 276 | C13H8OS3 | Seoul, Korea | [ | |
| EtOH/ | - | - | Seoul, Korea | [ | ||
| Tagetes minuta, aerial parts (Asteraceae) | MeOH/ | - | - | Al-Baha city, Saudi Arabia | [ | |
| 5-Hydroxymethyl-2,2′:5′,2′′- | MeOH/EtOAc-soluble fraction | 278 | C13H10OS3 | Seoul, Korea | [ | |
| EtOH/ | - | - | Seoul, Korea | [ | ||
| EtOH/ | - | - | Seoul, Korea | [ | ||
| 3′-Methoxy-2,2′:5′,2′′-terthiophene ( | MeOH/EtOAc-soluble fraction | 278 | C13H10OS3 | Seoul, Korea | [ | |
| 5-Hydroxymethyl-(2,2′:5′,2′′)-terthienyl angelate ( | EtOH/ | 360 | C18H16O2S3 | Seoul, Korea | [ | |
| 5-Hydroxymethyl-(2,2′:5′,2′′)-terthienyl tiglate ( | EtOH/ | 360 | C18H16O2S3 | Seoul, Korea | [ | |
| 5-Methoxy-(2,2′:5′,2′′)-terthiophene ( | EtOH/ | 292 | C14H12OS3 | Seoul, Korea | [ | |
| 3′-Hydroxy-2,2′:5′,2′′-terthiophene-3′-O-β-D-glucopyranoside ( | MeOH/EtOAc-soluble fraction | 426 | C18H18O6S3 | Seoul, Korea | [ | |
| IV. Quinquethiophenes | ||||||
| Thiotagetin A ( | Tagetes minuta, aerial parts, (Asteraceae) | MeOH/ | 540 | C27H24O2S5 | Al-Baha city, Saudi Arabia | [ |
| V. Miscellaneous | ||||||
| Sibiricumthionol ( | MeOH/CH2Cl2-soluble fraction | 197 | C9H11NO2S | Helen town, Heilongjiang, China | [ | |
| (+)-Xanthienopyran ( | MeOH/CH2Cl2-soluble fraction | 316 | C17H16O4S | Helen town, Heilongjiang, China | [ | |
| Rupestriene A ( | EtOH/CH3Cl-soluble fraction | 280 | C15H20O3S | Xinjiang Uygur Autonomous, | [ | |
| 7-[1-(Thiophene-5-yl)-1-formamido]-3-propylenyl-3-cephem-4-carboxylic acid (CAx1) ( | Endolithic | Spore MeOH extract | 350 | C15H14N2O4S2 | Granite rock, Mylliem, Meghalaya, India | [ |
| 2,5-Bis(5-tert-butyl-2-benzoxazolyl)thiophene ( | Marine-derived actinomycete | Fermentation broth | 430 | C26H26N2O2S | Cu Lao Cham- Quang Nam, Vietnam | [ |
| Thiocarboxylic A ( | EtOAc of fermented material | 332 | C18H20O4S | Xinning, Hunan, China | [ | |
| Thiocarboxylic B ( | EtOAc of fermented material | 376 | C19H20O6S | Xinning, Hunan, China | [ | |
| Thiocarboxylic C1 ( | EtOAc of fermented material | 348 | C18H20O5S | Xinning, Hunan, China | [ | |
| Thiocarboxylic C2 ( | EtOAc of fermented material | 348 | C18H20O5S | Xinning, Hunan, China | [ | |
| Thiocarboxylic D1 ( | EtOAc of fermented material | 350 | C18H22O5S | Xinning, Hunan, China | [ | |
| Thiocarboxylic D2 ( | EtOAc of fermented material | 350 | C18H22O5S | Xinning, Hunan, China | [ | |
| Rupestriene D ( | EtOH/PE-soluble fraction | 234 | C13H14O2S | Xinjiang Uygur Autonomous, | [ | |
| Rupestriene E ( | EtOH/EtOAc-soluble fraction | 294 | C15H18O4S | Xinjiang Uygur Autonomous, | [ | |
Scheme 1Proposed biosynthetic pathway of dimeric bithiophenes 68–70 from arctinol-b (49) [17].
Scheme 2Proposed biosynthetic pathway of 46 [44,52,53,54].
Biological activities of naturally occurring thiophenes.
| Compound Name | Biological Activity | Assay, Organism, or Cell Line | Biological Results | Ref. | |
|---|---|---|---|---|---|
| Compound | Positive Control | ||||
| Foetithiophene F ( | Antimicrobial | Broth microdilution/ | 50 µg/mL (MIC) | Gentamicin 10 µg/mL (MIC) | [ |
| 5-Propinyl-thiophene-2-carboxylic acid ( | In vitro anti-inflammatory/NO | LPS-stimulated production in BV-2 microglial cells | 79.5 µM (IC50) | Quercetin 16.3 µM (IC50) | [ |
| 3-Hydroxy-5-propinyl-2-acetyl-thiophene ( | In vitro anti-inflammatory/NO | LPS-stimulated production in BV-2 microglial cells | 98.5 µM (IC50) | Quercetin 16.3 µM (IC50) | [ |
| 2-(3,4-Dihydroxybut-1-ynyl)-5-(penta-1,3-diynyl)thiophene ( | In vitro anti-inflammatory/NO | LPS-stimulated production in the RAW 264.7 cell line | 2.5 µg/mL (IC50) | Indomethacin 65.4 µg/mL (IC50) | [ |
| Cytotoxicity | Resazurin reduction/CEM/ADR5000 | 21.09 µM (IC50) | Doxorubicin 195.12 µM (IC50) | [ | |
| Cytotoxicity | Resazurin reduction/CCRF-CEM | 46.96 µM (IC50) | Doxorubicin 0.20 µM (IC50) | [ | |
| Antimicrobial | INT/ | 64.0 µg/mL (MIC) | Chloramphenicol 64.0 µg/mL (MIC) | [ | |
| Antimicrobial | INT/ | 64.0 µg/mL (MIC) | Chloramphenicol 16.0 µg/mL (MIC) | [ | |
| Antimicrobial | INT/ | 64.0 µg/mL (MIC) | Chloramphenicol 16.0 µg/mL (MIC) | [ | |
| Antimicrobial | INT/ | 64.0 µg/mL (MIC) | Chloramphenicol 128.0 µg/mL (MIC) | [ | |
| Antimicrobial | INT/ | 256.0 µg/mL (MIC) | Chloramphenicol 256.0 µg/mL (MIC) | [ | |
| Antimicrobial | INT/ | 256.0 µg/mL (MIC) | Chloramphenicol 16.0 µg/mL (MIC) | [ | |
| 2-(Penta-1,3-diyn-1-yl)-5–(4-acetoxy-3-hydroxybuta-1-yn-1-yl) thiophene ( | CYP2A | Enzymatic reconstitution | 6.43 µM (IC50) | Methoxsalen 0.19 µM (IC50) | [ |
| CYP2A13 | Enzymatic reconstitution | 6.18 µM (IC50) | Methoxsalen 0.43 µM (IC50) | [ | |
| Echinothiophene A ( | Nematicidal | Nematode Mortality/J2s of | 0.42 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ |
| 1.44 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 0.5 µg/mL (MIC) | [ | |
| Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | ||
| 8.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | |||
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 256.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 4.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| Echinothiophene B ( | Nematicidal | Nematode Mortality/J2s of | 2.65 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ |
| 9.23 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 0.5 µg/mL (MIC) | [ | |
| Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 256.0 µg/mL (MIC) | Carbendazim 256.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 8.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 8.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| Echinothiophene C ( | Nematicidal | Nematode Mortality/J2s of | 16.55 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ |
| 18.17 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | |
| Broth microdilution/ | 256.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| 2-(Pro-1-ynyl)-5-(5,6-dihydroxypenta-1,3-diynyl) thiophene (PYDDT) ( | CYP2A6 inhibition | Enzymatic reconstitution | 3.90 µM (IC50) | Methoxsalen 0.19 µM (IC50) | [ |
| CYP2A13 inhibition | Enzymatic reconstitution | 2.40 µM (IC50) | Methoxsalen 0.43 µM (IC50) | [ | |
| 5-(1,2-Dihydroxyethyl)-2-( | In vitro anti-inflammatory/NO | LPS-stimulated production in the RAW 264.7 cell line | 28.2 µM (IC50) | -Indomethacin 13.2 µM (IC50) | [ |
| 5-(1,2-Dihydroxy-ethyl)-2-( | In vitro anti-inflammatory/NO | LPS-stimulated production in the RAW 264.7 cell line | 12.8 µM (IC50) | -Indomethacin 13.2 µM (IC50) | [ |
| 2-(Prop-1-inyl)-5-(6-acetoxy-5-hydroxyhexa-1,3-diinyl) thiophene ( | CYP2A6 inhibition | Enzymatic reconstitution | 4.44 µM (IC50) | Methoxsalen 0.19 µM (IC50) | [ |
| CYP2A13 inhibition | Enzymatic reconstitution | 2.94 µM (IC50) | Methoxsalen 0.43 µM (IC50) | [ | |
| 3′′ | In vitro anti-inflammatory/NO | LPS-stimulated production in RAW 264. | 84.5 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 3′′ | In vitro anti-inflammatory/NO | LPS-stimulated production in RAW 264.7 macrophages cells | 83.4 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 3′′-Ethoxy-3′′ | In vitro anti-inflammatory/NO | LPS-stimulated production in RAW 264.7 macrophages cells | 86.9 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| 3′′-Ethoxy-3′′ | In vitro anti-inflammatory/ | LPS-stimulated production in RAW 264.7 macrophages cells | 90.1 (NRC % inhibition) | Dexamethasone 62.2 (NRC % inhibition) | [ |
| Rupestriene B ( | In vitro anti-inflammatory/ | LPS-stimulated production in BV-2 microglial cells | 8.5 µM (IC50) | Quercetin 4.3 µM (IC50) | [ |
| Rupestriene C ( | In vitro anti-inflammatory/ | LPS-stimulated production in BV-2 microglial cells | 5.3 µM (IC50) | Quercetin 4.3 µM (IC50) | [ |
| 5-(3,4-Dihydroxybut-1-ynyl)-2,2′-bithiophene (33) | In vitro anti-inflammatory/ | LPS-stimulated production in the RAW 264.7 cell line | 20.0 µg/mL (IC50) | Indomethacin 65.4 µg/mL (IC50) | [ |
| 5-(But-3-en-1-ynyl)-2,2′-bithiophene (5-BBT) (37) | Fungicidal | Broth microdilution/ | 7.81 µg/mL (MFC) in light | Amphotericin B 0.50 µg/mL (MFC) | [ |
| Larvicidal | Larval mortality/Aedes albopictus | 0.34 µg/mL (LC50) | Rotenone 3.75 µg/mL (LC50) | [ | |
| Larvicidal | Larval mortality/Aedes albopictus | 0.72 µg/mL (LC95) | Rotenone 9.45 µg/mL (LC95) | [ | |
| Larvicidal | Larval mortality/Anopheles sinensis | 1.36 µg/mL (LC50) | Rotenone 1.25 µg/mL (LC50) | [ | |
| Larvicidal | Larval mortality/Anopheles sinensis | 1.93 µg/mL (LC95) | Rotenone 2.24 µg/mL (LC95) | [ | |
| Larvicidal | Larval mortality/Culex pipiens pallens | 0.12 µg/mL (LC50) | Rotenone 1.88 µg/mL (LC50) | [ | |
| Fungicidal | Larval mortality/Culex pipiens pallens | 0.18 µg/mL (LC95) | Rotenone 3.74 µg/mL (LC95) | [ | |
| Fungicidal | Broth microdilution/ | 62.50 µg/mL (MFC) in low oxygen and light | - | [ | |
| Fungicidal | Broth microdilution/ | 7.81 µg/mL (MFC) in normal oxygen and light | - | [ | |
| 5-(4-Isovaleroyloxybut-1-ynyl)-2,2′-bithiophene (5-IBT) ( | Larvicidal | Larval mortality/ | 0.45 µg/mL (LC50) | Rotenone 3.75 µg/mL (LC50) | [ |
| Larvicidal | 0.66 µg/mL (LC95) | Rotenone 9.45 µg/mL (LC95) | [ | ||
| Larvicidal | Larval mortality/ | 5.36 µg/mL (LC50) | Rotenone 1.25 µg/mL (LC50) | [ | |
| Larvicidal | 11.26 µg/mL (LC95) | Rotenone 2.24 µg/mL (LC95) | [ | ||
| Larvicidal | Larval mortality/ | 0.33 µg/mL (LC50) | Rotenone 1.88 µg/mL (LC50) | [ | |
| Larvicidal | 0.54 µg/mL (LC95) | Rotenone 3.74 µg/mL (LC95) | [ | ||
| 5-(4-Hydroxy-1-butynyl)-2,2′-bithiophene ( | In vitro anti-inflammatory/NO | LPS-stimulated production in the RAW 264.7 cell line | 6.7 µg/mL (IC50) | Indomethacin 65.4 µg/mL (IC50) | [ |
| Fungicidal | Broth microdilution/ | 3.90 µg/mL (MFC) in light | -Amphotericin B 0.50 µg/mL (MFC) | [ | |
| Antimicrobial | Broth microdilution/ | 8.0 µg/mL (MIC) | Levofloxacin 8.0 μg/mL (MIC) | [ | |
| Antimicrobial | Broth microdilution/ | 64.0 µg/mL (MIC) | Levofloxacin 16.0 μg/mL (MIC) | [ | |
| Antimicrobial | Broth microdilution/ | 64.0 µg/mL (MIC) | Levofloxacin 64.0 μg/mL (MIC) | [ | |
| Fungicidal | Broth microdilution/ | 250.0 µg/mL (MFC) in low oxygen and light | - | [ | |
| Fungicidal | Broth microdilution/ | 3.90 µg/mL (MFC) in normal oxygen and light | - | [ | |
| Anti-inflammatory | Colorimetric/5-LOX | 41.82 µM (IC50) | Indomethacin 0.89 µM (IC50) | [ | |
| 5-(4-Acetoxy-1-butynl)-2,2′-bithiophene ( | Fungicidal | Broth microdilution/ | 7.81 µg/mL (MFC) in light | -Amphotericin B 0.50 µg/mL (MFC) | [ |
| Fungicidal | Broth microdilution/ | 62.50 µg/mL (MFC) in low oxygen and light | - | [ | |
| Fungicidal | Broth microdilution/ | 7.81 µg/mL (MFC) in normal oxygen and light | - | [ | |
| 6-Methoxy-arctinol-b ( | In vitro anti-inflammatory/NO | LPS-stimulated production in the RAW 264.7 cell line | 30.6 µM (IC50) | -Indomethacin 13.2 µM (IC50) | [ |
| Nematicidal | Nematode Mortality/J2s of | 5.83 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ | |
| 7.05 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 0.5 µg/mL (MIC) | [ | |
| Broth microdilution/ | 256.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| Arctinol-b ( | In vitro anti-inflammatory/NO | LPS-stimulated production in the RAW 264.7 cell line | 48.7 µM (IC50) | -Indomethacin 13.2 µM (IC50) | [ |
| Antimicrobial | Broth microdilution/ | 8.0 µg/mL (MIC) | Levofloxacin 8.0 μg/mL (MIC) | [ | |
| Antimicrobial | Broth microdilution/ | 64.0 µg/mL (MIC) | Levofloxacin 16.0 μg/mL (MIC) | [ | |
| Antimicrobial | Broth microdilution/ | 64.0 µg/mL (MIC) | Levofloxacin 64.0 μg/mL (MIC) | [ | |
| Nematicidal | Nematode Mortality/J2s of | 13.48 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ | |
| 14.72 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 256.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | |
| Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 256.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| Arctinone-b ( | Nematicidal | Nematode Mortality/J2s of | 1.14 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ |
| 2.00 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 256.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | |
| Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| Arctinol ( | Nematicidal | Nematode Mortality/J2s of | 15.90 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ |
| 17.82 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 256.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | |
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 256.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| Arctinal ( | Antimicrobial | Broth microdilution/ | 32.0 µg/mL (MIC) | Levofloxacin 8.0 μg/mL (MIC) | [ |
| Antimicrobial | Broth microdilution/ | 64.0 µg/mL (MIC) | Levofloxacin 16.0 μg/mL (MIC) | [ | |
| Nematicidal | Nematode Mortality/J2s of | 2.62 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ | |
| 8.75 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | |
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| Arctinol A ( | Antimicrobial | Broth microdilution/ | 8.0 µg/mL (MIC) | Levofloxacin 8.0 μg/mL (MIC) | [ |
| Antimicrobial | Broth microdilution/ | 64.0 µg/mL (MIC) | Levofloxacin 16.0 μg/mL (MIC) | [ | |
| 5′-(3,4-Dihydroxybut-1-yn-1-yl)-[2,2′-bithiophene]-5-carbaldehyde ( | Antimicrobial | Broth microdilution/ | 128.0 µg/mL (MIC) | Levofloxacin 8.0 μg/mL (MIC) | [ |
| Antimicrobial | Broth microdilution/ | 256.0 µg/mL (MIC) | Levofloxacin 16.0 μg/mL (MIC) | [ | |
| Antimicrobial | Broth microdilution/ | 256.0 µg/mL (MIC) | Levofloxacin 64.0 μg/mL (MIC) | [ | |
| 4-Hydroxy-1-(5′-methyl-[2,2′-bithiophen]-5-yl)butan-1-one ( | Antimicrobial | Broth microdilution/ | 8.0 µg/mL (MIC) | Levofloxacin 8.0 μg/mL (MIC) | [ |
| Antimicrobial | Broth microdilution/ | 32.0 µg/mL (MIC) | Levofloxacin 16.0 μg/mL (MIC) | [ | |
| Antimicrobial | 32.0 µg/mL (MIC) | Levofloxacin 64.0 μg/mL (MIC) | [ | ||
| 5′-(3,4-Dihydroxybut-1-yn-1-yl)-[2,2′-bithiophene]-5-carboxylic acid ( | Antimicrobial | 256.0 µg/mL (MIC) | Levofloxacin 8.0 μg/mL (MIC) | [ | |
| Echinothiophene D ( | Nematicidal | Nematode Mortality/J2s of | 2.57 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ |
| 1.80 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 0.5 µg/mL (MIC) | [ | |
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 256.0 µg/mL (MIC) | Carbendazim 256.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 8.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| Echinothiophene E ( | Nematicidal | Nematode Mortality/J2s of | 8.28 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ |
| 9.12 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 0.5 µg/mL (MIC) | [ | |
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 256.0 µg/mL (MIC) | Carbendazim 256.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| Echinothiophene F ( | Nematicidal | Nematode Mortality/J2s of | 20.13 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ |
| 18.41 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | |
| Broth microdilution/ | 256.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| 2-Prop-1-inyl-5′-(2-hydroxy-3-chloropropyl) dithiophene ( | Nematicidal | Nematode Mortality/J2s of | 0.91 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ |
| 0.86 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 0.5 µg/mL (MIC) | [ | |
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 4.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 256.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 4.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 4.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | ||
| Ecliprostin A ( | Antibacterial | Broth microdilution/ | 25.0 µM (MIC) | Penicillin 0.156 µM (MIC) | [ |
| Ecliprostin B ( | Antibacterial | Broth microdilution/ | 6.25 µM (MIC) | Penicillin 0.156 µM (MIC) | [ |
| Ecliprostin C ( | Antibacterial | Broth microdilution/ | 25.0 µM (MIC) | Penicillin 0.156 µM (MIC) | [ |
| Echinbithiophenedimer A ( | Nematicidal | Nematode Mortality/J2s of | 16.53 µg/mL (LC50) in light | Ethoprophos 36.15 (LC50) in light | [ |
| 18.17 µg/mL (LC50) in dark | Ethoprophos 31.94 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | |
| Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 64.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 256.0 µg/mL (MIC) | [ | ||
| Echinbithiophenedimer B ( | Nematicidal | Nematode Mortality/J2s of | 13.88 µg/mL (LC50) in light | Ethoprophos 36.15 (LC50) in light | [ |
| 16.28 µg/mL (LC50) in dark | Ethoprophos 31.94 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | |
| Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 16.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 256.0 µg/mL (MIC) | [ | ||
| Echinbithiophenedimer C ( | Nematicidal | Nematode Mortality/J2s of | 8.73 µg/mL (LC50) in light | Ethoprophos 36.15 (LC50) in light | [ |
| 9.39 µg/mL (LC50) in dark | Ethoprophos 31.94 (LC50) in dark | [ | |||
| Antifungal | Broth microdilution/ | 8.0 µg/mL (MIC) | Carbendazim 16.0 µg/mL (MIC) | [ | |
| Broth microdilution/ | 8.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 8.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 32.0 µg/mL (MIC) | Carbendazim 2.0 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 128.0 µg/mL (MIC) | Carbendazim 256.0 µg/mL (MIC) | [ | ||
| 4-(5′-(hydroxymethyl)-[2,2′-bithiophene]-5-yl)but-3-yn-1-ol) (Thio1) ( | Anthelmintic | Larval development test/ | 0.3243 mg/mL (EC50) | Levamisole 1.88 mg/mL (EC50) | [ |
| Anthelmintic | Fecal egg count reduction test/ | 0.1731 mg/mL (EC50) | Levamisole 1.88 mg/mL (EC50) | [ | |
| 2,2′:5′,2′′-Terthiophene (α-Terthienyl) ( | Cytotoxicity | MTT/SKOV3 | 77.23 µM (IC50) | Cisplatin 11.25 µM (IC50) | [ |
| Fungicidal | Broth microdilution/ | 0.24 µg/mL (MFC) in light | Amphotericin B 0.50 µg/mL (MFC) | [ | |
| Fungicidal | Broth microdilution/ | 7.81 µg/mL (MFC) in low oxygen and light | - | [ | |
| Fungicidal | Broth microdilution/ | 0.24 µg/mL (MFC) in normal oxygen and light | - | [ | |
| Larvicidal | Larval mortality/ | 1.41 µg/mL (LC50) | Rotenone 3.75 µg/mL (LC50) | [ | |
| Larvicidal | 2.19 µg/mL (LC95) | Rotenone 9.45 µg/mL (LC95) | [ | ||
| Larvicidal | Larval mortality/ | 1.79 µg/mL (LC50) | Rotenone 1.25 µg/mL (LC50) | [ | |
| Larvicidal | 2.54 µg/mL (LC95) | Rotenone 2.24 µg/mL (LC95) | [ | ||
| Larvicidal | Larval mortality/ | 1.38 µg/mL (LC50) | Rotenone 1.88 µg/mL (LC50) | [ | |
| Larvicidal | 2.15 µg/mL (LC95) | Rotenone 3.74 µg/mL (LC95) | [ | ||
| Nematicidal | Nematode Mortality/J2s of | 0.56 µg/mL (LC50) in light | Abamectin 8.73 (LC50) in light | [ | |
| 1.77 µg/mL (LC50) in dark | Abamectin 9.38 (LC50) in dark | [ | |||
| 5-Formyl-2,2′:5′,2′′-terthiophene (Ecliptal) ( | Cytotoxicity | MTT/SKOV3 | 24.57 µM (IC50) | Cisplatin 11.25 µM (IC50) | [ |
| Cytotoxicity | MTT/Hec1A | 12.00 µM (IC50) | Cisplatin 120.42 µM (IC50) | [ | |
| Cytotoxicity | MTT/Ishikawa | 2.20 µM (IC50) | Cisplatin 10.11 µM (IC50) | [ | |
| Anti-inflammatory | Colorimetric/5-LOX | 26.18 µM (IC50) | Indomethacin 0.89 µM (IC50) | [ | |
| Antibacterial | Broth microdilution/ | 25.0 µM (MIC) | Penicillin G 0.156 µM (MIC) | [ | |
| 5-Hydroxymethyl-2,2′:5′,2′′-terthiophene (α-Terthienylmethanol) | Cytotoxicity | MTT/SKOV3 | 7.73 µM (IC50) | Cisplatin 11.25 µM (IC50) | [ |
| Cytotoxicity | MTT/Hec1A | 0.38 µM (IC50) | Cisplatin 120.42 µM (IC50) | [ | |
| Cytotoxicity | MTT/Ishikawa | 0.35 µM (IC50) | Cisplatin 10.11 µM (IC50) | [ | |
| Cytotoxicity | MTT/A2780 | 1.18 µM (IC50) | Cisplatin 10.80 µM (IC50) | [ | |
| Cytotoxicity | MTT/SKOV3 | 15.51 µM (IC50) | Cisplatin 43.05 µM (IC50) | [ | |
| Cytotoxicity | MTT/OVCAR3 | 0.20 µM (IC50) | Cisplatin 35.46 µM (IC50) | [ | |
| Cytotoxicity | MTT/ES2 | 18.82 µM (IC50) | Cisplatin 29.58 µM (IC50) | [ | |
| Antibacterial | Broth microdilution/ | 25.0 µM (MIC) | Penicillin G 0.156 µM (MIC) | [ | |
| 5-Hydroxymethyl-(2,2′:5′,2′′)-terthienyl angelate ( | Cytotoxicity | MTT/Hec1A | 129.85 µM (IC50) | Cisplatin 120.42 µM (IC50) | [ |
| Cytotoxicity | MTT/Ishikawa | 6.87 µM (IC50) | Cisplatin 10.11 µM (IC50) | [ | |
| 5-Hydroxymethyl-(2,2′:5′,2′′)-terthienyl tiglate ( | Cytotoxicity | MTT/Hec1A | 2.66 µM (IC50) | Cisplatin 120.42 µM (IC50) | [ |
| Cytotoxicity | MTT/Ishikawa | 9.68 µM (IC50) | Cisplatin 10.11 µM (IC50) | [ | |
| 5-Methoxy-(2,2′:5′,2′′)-terthiophene ( | Cytotoxicity | MTT/Hec1A | 1.38 µM (IC50) | Cisplatin 120.42 µM (IC50) | [ |
| Cytotoxicity | MTT/Ishikawa | 7.12 µM (IC50) | Cisplatin 10.11 µM (IC50) | [ | |
| 3′-Hydroxy-2,2′:5′,2′′-terthiophene-3′-O-β-D-glucopyranoside ( | Cytotoxicity | 58.20 µM (IC50) | Cisplatin 11.25 µM (IC50) | [ | |
| Thiotagetin A ( | Cytotoxicity | MTT/KB | 2.03 μg/mL (ED50) | Adriamycin 0.26 μg/mL (ED50) | [ |
| Cytotoxicity | MTT/MCF-7 | 3.88 μg/mL (ED50) | Adriamycin 0.07 μg/mL (ED50) | [ | |
| Rupestriene A ( | In vitro anti-inflammatory/ | LPS-stimulated production in BV-2 microglial cells | 20.3 µM (IC50) | Quercetin 4.3 µM (IC50) | [ |
| Neuraminidase inhibitory activity | Fluorescence-based assay | 351.15 µM (IC50) | Oseltamivir acid 77.91 µM (IC50) | [ | |
| 7-[1-(Thiophene-5-yl)-1-formamido]-3-propylenyl-3-cephem-4-carboxylic acid (CAx1) ( | Antibacterial | Broth microdilution/ | 0.2 µg/mL (MIC) | Penicillin 32.0 µg/mL (MIC) | [ |
| Antibacterial | Broth microdilution/ | 0.25 µg/mL (MIC) | Penicillin 0.5 µg/mL (MIC) | [ | |
| Antibacterial | Broth microdilution/ | 4.0 µg/mL (MIC) | Penicillin 4.0 µg/mL (MIC) | [ | |
| Antibacterial | Broth microdilution/ | 4.0 µg/mL (MIC) | Penicillin 16.0 µg/mL (MIC) | [ | |
| 2,5-Bis(5-tert-butyl-2-benzoxazolyl)thiophene ( | Antimicrobial | Broth microdilution/ | 256.0 µg/mL (MIC) | Streptomycin 256.0 μg/mL (MIC) | [ |
| Thiocarboxylic A ( | Antimicrobial | Broth microdilution/ | 1.7 µg/mL (MIC) | Streptomycin 2.3 µg/mL (MIC) | [ |
| Broth microdilution/ | 1.7 µg/mL (MIC) | Streptomycin 0.1 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 3.3 µg/mL (MIC) | Amphotericin B 0.1 µg/mL (MIC) | [ | ||
| Thiocarboxylic B ( | Antimicrobial | Broth microdilution/ | 0.9 µg/mL (MIC) | Streptomycin 2.3 µg/mL (MIC) | [ |
| Broth microdilution/ | 1.9 µg/mL (MIC) | Streptomycin 0.1 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 3.9 µg/mL (MIC) | Amphotericin B 0.1 µg/mL (MIC) | [ | ||
| Thiocarboxylic C1 ( | Antimicrobial | Broth microdilution/ | 7.0 µg/mL (MIC) | Streptomycin 2.3 µg/mL (MIC) | [ |
| Broth microdilution/ | 3.5 µg/mL (MIC) | Streptomycin 0.1 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 7.0 µg/mL (MIC) | Amphotericin B 0.1 µg/mL (MIC) | [ | ||
| Thiocarboxylic C2 ( | Antimicrobial | Broth microdilution/ | 7.0 µg/mL (MIC) | Streptomycin 2.3 µg/mL (MIC) | [ |
| Broth microdilution/ | 3.5 µg/mL (MIC) | Streptomycin 0.1 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 7.0 µg/mL (MIC) | Amphotericin B 0.1 µg/mL (MIC) | [ | ||
| Thiocarboxylic D1 ( | Antimicrobial | Broth microdilution/ | 3.5 µg/mL (MIC) | Streptomycin 2.3 µg/mL (MIC) | [ |
| Broth microdilution/ | 3.5 µg/mL (MIC) | Streptomycin 0.1 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 7.0 µg/mL (MIC) | Amphotericin B 0.1 µg/mL (MIC) | [ | ||
| Thiocarboxylic D2 ( | Antimicrobial | Broth microdilution/ | 3.5 µg/mL (MIC) | Streptomycin 2.3 µg/mL (MIC) | [ |
| Broth microdilution/ | 3.5 µg/mL (MIC) | Streptomycin 0.1 µg/mL (MIC) | [ | ||
| Broth microdilution/ | 7.0 µg/mL (MIC) | Amphotericin B 0.1 µg/mL (MIC) | [ | ||
| Rupestriene D ( | Neuraminidase inhibitory activity | Fluorescence-based assay | 986.54 µM (IC50) | Oseltamivir acid 77.91 µM (IC50) | [ |
| Rupestriene E ( | Neuraminidase inhibitory activity | Fluorescence-based assay | 365.40 µM (IC50) | Oseltamivir acid 77.91 µM (IC50) | [ |
Figure 3Structures of monothiophenes 1–11.
Figure 4Structures of monothiophenes 12–21.
Figure 5Structures of monothiophenes 22–31.
Figure 6Structures of compounds 32–41.
Figure 7Structures of bithiophenes 42–52.
Figure 8Structures of bithiophenes 53–63.
Figure 9Structures of bithiophenes 64–72.
Figure 10Structures of bithiophenes (73 and 74), terthiophenes (75–82), and quinquethiophene 83.
Figure 11Structures of miscellaneous thiophenes 84–96.
The probability and model accuracy prediction for thiophene derivatives against Cathepsin D using SuperPred target prediction webserver.
| 9 | Probability * | Model Accuracy ** |
|---|---|---|
| 9 | 96.04% | 96.09% |
| 20 | 93.69% | 96.09% |
| 28 | 82.30% | 98.95% |
| 29 | 85.79% | 98.95% |
| 30 | 82.76% | 98.95% |
| 33 | 87.63% | 98.95% |
| 43 | 82.00% | 98.95% |
| 46 | 94.79% | 98.95% |
| 57 | 89.12% | 98.95% |
| 67 | 91.20% | 98.95% |
| 68 | 77.77% | 90.17% |
| 70 | 88.21% | 98.95% |
| 75 | 79.91% | 98.95% |
| 76 | 87.50% | 98.95% |
| 77 | 85.75% | 98.95% |
| 80 | 90.87% | 98.95% |
| 81 | 90.32% | 98.95% |
| 82 | 88.71% | 98.95% |
* The input structure binds with the specific target, as determined by the respective target machine learning model; ** Since the model performances vary between different targets, additionally, the 10-fold cross-validation score of the respective logistic regression model is displayed.
In silico predicted ADME properties of the thiophenes derivatives.
| Title | mol MW | # Stars | Dipole | SASA | DonorHB | AccptHB | QPlogPo/w | QPlogS | QPlogKhsa | # Metab | QPlogBB | %HumOral | QPlogHERG | CNS | # RtvFG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recommended range | (130–725) | (0.0–5.0) | (1–12.50) | (300–1000) | (0–6) | (2.0–20.0) | (−2–6.5) | (−6.5–0.5) | (−1.5–1.5) | (1–8) | (−3–1.2) | (<25% poor; >80% high) | concern below −5 | (−2 inactive) (+2 active) | (0–2) |
| 1 | 170.23 | 1 | 2.8 | 375.85 | 1 | 2 | 2.15 | −2.47 | −0.34 | 4 | −0.19 | 83.82 | −1.25 | −1 | - |
| 2 | 218.33 | - | 7.35 | 456.52 | - | 4 | 2.1 | −1.26 | −0.4 | 6 | 0.01 | 75.45 | −3.63 | 1 | - |
| 2 | 218.33 | - | 7.35 | 456.52 | - | 4 | 2.1 | −1.26 | −0.4 | 6 | 0.01 | 75.45 | −3.63 | 1 | - |
| 3 | 186.33 | 5 | 3.11 | 416.69 | - | 0.5 | 3.73 | −4.49 | 0.38 | 5 | 0.61 | 100 | −3.22 | 2 | - |
| 4 | 310.53 | 7 | 0.48 | 576.92 | - | 0.5 | 5.35 | −8.24 | 1.34 | 10 | 0.96 | 100 | −3.9 | 2 | - |
| 5 | 202.33 | - | 5.95 | 441.45 | - | 4 | 2.01 | −1.08 | −0.44 | 6 | 0.24 | 78.76 | −3.53 | 1 | - |
| 5 | 202.33 | - | 5.95 | 441.45 | - | 4 | 2.01 | −1.08 | −0.44 | 6 | 0.24 | 78.76 | −3.53 | 1 | - |
| 6 | 188.35 | 5 | 2.31 | 409.89 | - | 1 | 3.11 | −3.82 | 0.3 | 3 | 0.45 | 100 | −2.88 | 1 | - |
| 7 | 166.19 | - | 3.67 | 386.76 | 1 | 2 | 1.96 | −1.92 | −0.42 | 2 | −0.4 | 80.8 | −2.35 | −1 | - |
| 8 | 180.22 | 3 | 6.7 | 417.32 | - | 1.75 | 2.21 | −2.75 | −0.11 | 3 | −0.39 | 95.04 | −4.18 | - | - |
| 8 | 180.22 | 3 | 6.61 | 417.82 | - | 1.75 | 2.22 | −2.76 | −0.11 | 3 | −0.39 | 95.17 | −4.18 | - | - |
| 9 | 230.28 | - | 3.18 | 547.88 | 2 | 3.4 | 2.52 | −4.13 | −0.08 | 4 | −0.8 | 95.43 | −5.93 | −1 | - |
| 9 | 230.28 | - | 3.09 | 547.44 | 2 | 3.4 | 2.52 | −4.12 | −0.08 | 4 | −0.8 | 95.42 | −5.92 | −1 | - |
| 10 | 214.28 | 1 | 2.07 | 536.85 | 1 | 1.7 | 3.7 | −4.76 | 0.3 | 4 | −0.22 | 100 | −5.9 | - | - |
| 11 | 256.32 | - | 3.01 | 596.59 | - | 2.7 | 3.92 | −5.33 | 0.4 | 4 | −0.73 | 100 | −6.01 | −1 | 1 |
| 11 | 256.32 | - | 3.22 | 600.04 | - | 2.7 | 3.91 | −5.41 | 0.4 | 4 | −0.77 | 100 | −6.07 | −1 | 1 |
| 12 | 272.32 | - | 4.71 | 639.64 | 1 | 3.7 | 3.61 | −5.81 | 0.34 | 3 | −1.03 | 100 | −6.48 | −2 | 1 |
| 12 | 272.32 | - | 4.76 | 640.28 | 1 | 3.7 | 3.61 | −5.82 | 0.34 | 3 | −1.03 | 100 | −6.49 | −2 | 1 |
| 13 | 286.35 | - | 4.06 | 664.62 | - | 3.7 | 4.35 | −6.09 | 0.44 | 4 | −0.45 | 100 | −6.48 | - | 1 |
| 13 | 286.35 | - | 4.29 | 664.92 | - | 3.7 | 4.36 | −6.11 | 0.44 | 4 | −0.44 | 100 | −6.46 | - | 1 |
| 14 | 290.76 | 1 | 5.18 | 641.98 | - | 2 | 5.2 | −7.01 | 0.83 | 3 | −0.19 | 100 | −6.36 | - | 2 |
| 14 | 290.76 | 1 | 5.25 | 642.37 | - | 2 | 5.2 | −7.01 | 0.83 | 3 | −0.18 | 100 | −6.36 | - | 2 |
| 15 | 248.73 | 1 | 5.08 | 543.19 | 1 | 1.7 | 4.16 | −5.53 | 0.46 | 3 | 0.24 | 100 | −5.84 | 1 | - |
| 16 | 290.76 | 1 | 3.84 | 623.15 | - | 2 | 5.14 | −6.93 | 0.85 | 3 | 0.1 | 100 | −6.22 | 1 | 1 |
| 17 | 398.52 | 2 | 2.11 | 825.87 | - | 4 | 6.39 | −8.4 | 1.32 | 5 | −0.97 | 100 | −6.6 | −1 | 2 |
| 18 | 230.28 | - | 3.09 | 548.17 | 2 | 3.4 | 2.52 | −4.13 | −0.08 | 4 | −0.8 | 95.44 | −5.93 | −1 | - |
| 18 | 230.28 | - | 3.07 | 548.16 | 2 | 3.4 | 2.52 | −4.13 | −0.08 | 4 | −0.8 | 95.44 | −5.93 | −1 | - |
| 19 | 232.3 | - | 3.57 | 540.4 | 2 | 3.4 | 2.59 | −3.96 | −0.05 | 4 | −0.68 | 100 | −5.63 | - | - |
| 19 | 232.3 | - | 3.49 | 538.9 | 2 | 3.4 | 2.64 | −3.94 | −0.06 | 4 | −0.61 | 100 | −5.6 | - | - |
| 20 | 232.3 | - | 3.7 | 536.62 | 2 | 3.4 | 2.57 | −3.9 | −0.06 | 4 | −0.67 | 100 | −5.55 | - | - |
| 20 | 232.3 | - | 1.64 | 534.91 | 2 | 3.4 | 2.62 | −3.87 | −0.06 | 4 | −0.6 | 100 | −5.5 | - | - |
| 21 | 244.31 | - | 2.9 | 571.71 | 1 | 3.4 | 3.53 | −4.67 | 0.15 | 5 | −0.27 | 100 | −5.9 | - | - |
| 21 | 244.31 | - | 2.85 | 572.08 | 1 | 3.4 | 3.53 | −4.68 | 0.15 | 5 | −0.27 | 100 | −5.91 | - | - |
| 22 | 256.32 | - | 3.42 | 600.19 | - | 2.7 | 3.91 | −5.41 | 0.4 | 4 | −0.77 | 100 | −6.08 | −1 | 1 |
| 22 | 256.32 | - | 3.45 | 600.15 | - | 2.7 | 3.91 | −5.41 | 0.4 | 4 | −0.77 | 100 | −6.08 | −1 | 1 |
| 23 | 230.28 | - | 3.18 | 547.88 | 2 | 3.4 | 2.52 | −4.13 | −0.08 | 4 | −0.8 | 95.43 | −5.93 | −1 | - |
| 24 | 272.32 | - | 4.71 | 639.63 | 1 | 3.7 | 3.61 | −5.81 | 0.34 | 3 | −1.03 | 100 | −6.48 | −2 | 1 |
| 25 | 258.33 | - | 2.66 | 619.03 | 1 | 3.4 | 4 | −5.37 | 0.3 | 5 | −0.35 | 100 | −6.24 | - | - |
| 26 | 300.37 | 2 | 4.36 | 710.36 | - | 3.7 | 4.83 | −6.8 | 0.61 | 4 | −0.55 | 100 | −6.73 | - | 1 |
| 27 | 234.31 | - | 3.3 | 548.83 | - | 2.7 | 3.45 | −4.13 | 0.11 | 5 | −0.82 | 100 | −5.6 | −1 | 1 |
| 28 | 234.31 | 1 | 6.27 | 543.84 | - | 2.7 | 3.44 | −4.03 | 0.09 | 5 | −0.77 | 100 | −5.53 | −1 | 1 |
| 29 | 414.47 | 2 | 4.68 | 754.8 | 6 | 13.6 | -0.11 | −2.92 | −1.06 | 8 | −3.29 | 40.05 | −5.89 | −2 | 1 |
| 29 | 414.47 | 2 | 4.64 | 734.02 | 6 | 13.6 | -0.19 | −2.69 | −1.1 | 8 | −3.13 | 40.7 | −5.7 | −2 | 1 |
| 29 | 414.47 | 2 | 5.17 | 755.35 | 6 | 13.6 | -0.19 | −2.92 | −1.08 | 8 | −3.35 | 39.14 | −5.94 | −2 | 1 |
| 29 | 414.47 | 2 | 5.73 | 728.91 | 6 | 13.6 | -0.23 | −2.61 | −1.08 | 8 | −3.16 | 39.41 | −5.63 | −2 | 1 |
| 30 | 386.42 | - | 2.77 | 688.65 | 6 | 13.6 | -0.66 | −2.47 | −1.18 | 7 | −2.88 | 39.15 | −5.64 | −2 | 1 |
| 30 | 386.42 | - | 3.22 | 682.74 | 6 | 13.6 | -0.75 | −2.36 | −1.15 | 7 | −2.99 | 36.13 | −5.48 | −2 | 1 |
| 30 | 386.42 | 1 | 4.11 | 714.6 | 6 | 13.6 | -0.74 | −2.75 | −1.18 | 7 | −3.27 | 34.82 | −5.96 | −2 | 1 |
| 30 | 386.42 | 1 | 1.2 | 710.72 | 6 | 13.6 | -0.73 | −2.7 | −1.18 | 7 | −3.22 | 35.33 | −5.91 | −2 | 1 |
| 31 | 232.3 | - | 2.7 | 541.33 | 2 | 3.4 | 2.43 | −3.82 | −0.08 | 4 | −0.79 | 95.57 | −5.54 | −1 | - |
| 31 | 232.3 | - | 2.84 | 542.23 | 2 | 3.4 | 2.43 | −3.84 | −0.08 | 4 | −0.8 | 95.44 | −5.56 | −1 | - |
| 32 | 264.36 | - | 1.82 | 533.75 | 1 | 3.4 | 3.52 | −4.3 | 0.12 | 5 | −0.08 | 100 | −5.49 | - | - |
| 32 | 264.36 | - | 1.93 | 538.34 | 1 | 3.4 | 3.54 | −4.4 | 0.13 | 5 | −0.08 | 100 | −5.56 | - | - |
| 33 | 250.33 | - | 2.38 | 509.39 | 2 | 3.4 | 2.66 | −3.76 | −0.09 | 4 | −0.56 | 96.23 | −5.48 | - | - |
| 33 | 250.33 | - | 2.37 | 509.81 | 2 | 3.4 | 2.66 | −3.77 | −0.09 | 4 | −0.56 | 96.24 | −5.49 | - | - |
| 34 | 208.29 | - | 4.09 | 422.53 | - | 2 | 3.01 | −3.34 | 0.01 | 2 | 0.23 | 100 | −4.42 | 1 | - |
| 35 | 194.27 | - | 4.61 | 394.08 | - | 2 | 2.75 | −2.53 | −0.14 | 2 | 0.03 | 100 | −4.24 | 1 | - |
| 36 | 224.29 | - | 3.29 | 451.72 | - | 2 | 3.15 | −3.89 | 0.14 | 2 | 0.14 | 100 | −4.8 | 1 | - |
| 37 | 216.32 | 5 | 0.44 | 474.39 | - | - | 5.8 | −5.65 | 0.72 | 2 | 0.35 | 100 | −5.56 | 1 | - |
| 38 | 318.45 | 1 | 3.17 | 674.19 | - | 2 | 5.85 | −7.32 | 1.08 | 4 | −0.2 | 100 | −6.41 | - | 1 |
| 39 | 432.63 | 9 | 0.65 | 807.6 | - | - | 11.73 | −12.03 | 2.41 | 6 | 0.5 | 100 | −8.14 | 2 | - |
| 39 | 432.63 | 8 | 0.93 | 700.3 | - | - | 9.78 | −11.17 | 2.17 | 6 | 0.52 | 100 | −6.51 | 2 | - |
| 40 | 432.63 | 9 | 0.65 | 807.6 | - | - | 11.73 | −12.03 | 2.41 | 6 | 0.5 | 100 | −8.14 | 2 | - |
| 40 | 432.63 | 8 | 0.93 | 700.3 | - | - | 9.78 | −11.17 | 2.17 | 6 | 0.52 | 100 | −6.51 | 2 | - |
| 41 | 334.45 | - | 4.91 | 630.13 | 1 | 3.7 | 4.38 | −5.51 | 0.58 | 4 | −0.77 | 100 | −5.67 | −1 | 1 |
| 41 | 334.45 | - | 4.93 | 626.38 | 1 | 3.7 | 4.38 | −5.47 | 0.58 | 4 | −0.74 | 100 | −5.58 | −1 | 1 |
| 42 | 334.45 | - | 4.82 | 652.88 | 1 | 3.7 | 4.57 | −5.96 | 0.64 | 5 | −0.76 | 100 | −5.95 | −1 | 1 |
| 42 | 334.45 | - | 4.4 | 673.42 | 1 | 3.7 | 4.8 | −6.38 | 0.68 | 5 | −0.64 | 100 | −6.24 | - | 1 |
| 43 | 234.33 | 1 | 2.01 | 498.72 | 1 | 1.7 | 3.71 | −4.39 | 0.27 | 4 | −0.03 | 100 | −5.45 | - | - |
| 44 | 276.37 | - | 2.76 | 592.07 | - | 2 | 4.28 | −6.08 | 0.67 | 3 | −0.21 | 100 | −6.15 | - | 1 |
| 45 | 210.27 | - | 3.5 | 401.73 | 1 | 2 | 2.72 | −3.04 | −0.23 | 2 | −0.22 | 85.2 | −2.48 | −1 | - |
| 46 | 388.97 | 2 | 4.59 | 617.73 | - | 2 | 6.5 | −6.17 | 1.21 | 8 | 0.19 | 100 | −4.68 | 1 | 2 |
| 46 | 388.97 | 1 | 6.57 | 609.65 | - | 2 | 6.37 | −6.02 | 1.17 | 8 | 0.12 | 100 | −4.58 | 1 | 2 |
| 47 | 252.35 | - | 4.52 | 495.92 | 1 | 3.7 | 2.67 | −3.53 | −0.07 | 4 | −0.5 | 96.52 | −4.88 | - | - |
| 48 | 278.38 | - | 2.94 | 560.83 | 1 | 3.4 | 3.75 | −4.74 | 0.27 | 6 | −0.12 | 100 | −5.36 | - | - |
| 49 | 264.36 | - | 2.49 | 532.94 | 2 | 3.4 | 2.98 | −4.12 | 0.04 | 5 | −0.44 | 100 | −5.28 | - | - |
| 50 | 246.34 | - | 5.04 | 515.59 | - | 2 | 3.88 | −4.92 | 0.41 | 3 | 0.1 | 100 | −5.25 | 1 | - |
| 51 | 248.31 | - | 4.21 | 494.76 | 1 | 2 | 3.56 | −4.39 | 0.13 | 3 | −0.42 | 90.16 | −3.34 | −1 | - |
| 52 | 232.32 | - | 5.54 | 487.09 | - | 2 | 3.35 | −4.29 | 0.26 | 3 | −0.13 | 100 | −5.11 | - | - |
| 53 | 234.33 | 1 | 1.8 | 496.6 | 1 | 1.7 | 3.64 | −4.49 | 0.3 | 4 | 0.05 | 100 | −5.21 | 1 | - |
| 54 | 248.31 | - | 4.21 | 495.1 | 1 | 2 | 3.57 | −4.39 | 0.13 | 3 | −0.42 | 90.17 | −3.35 | −1 | - |
| 55 | 262.34 | - | 4.22 | 544.7 | - | 2 | 4.12 | −5.47 | 0.54 | 3 | 0 | 100 | −5.55 | - | - |
| 56 | 304.42 | 4 | 1.89 | 591.79 | - | 1.5 | 5.59 | −6.89 | 1.06 | 4 | 0.15 | 100 | −5.48 | 1 | 1 |
| 56 | 304.42 | 4 | 1.89 | 591.47 | - | 1.5 | 5.58 | −6.9 | 1.07 | 4 | 0.15 | 100 | −5.46 | 1 | 1 |
| 57 | 278.34 | 1 | 2.8 | 547.2 | 2 | 5.4 | 1.7 | −3.68 | −0.27 | 4 | −1.47 | 77.15 | −5.44 | −2 | - |
| 57 | 278.34 | 1 | 3.43 | 547.55 | 2 | 5.4 | 1.7 | −3.69 | −0.27 | 4 | −1.47 | 77.15 | −5.45 | −2 | - |
| 58 | 266.37 | - | 4.99 | 531.75 | 1 | 3.7 | 2.98 | −4.13 | 0.1 | 5 | −0.56 | 100 | −4.91 | - | - |
| 59 | 294.34 | 1 | 1.92 | 555.27 | 3 | 5.4 | 1.93 | −3.98 | −0.45 | 4 | −1.78 | 62.81 | −3.68 | −2 | - |
| 59 | 294.34 | 1 | 2.76 | 555.53 | 3 | 5.4 | 1.93 | −3.98 | −0.45 | 4 | −1.78 | 62.81 | −3.68 | −2 | - |
| 60 | 248.36 | 1 | 2.19 | 534.06 | 1 | 1.7 | 4.03 | −5.03 | 0.44 | 5 | −0.06 | 100 | −5.44 | - | - |
| 61 | 298.37 | - | 5.85 | 542.89 | 3 | 7.1 | 1.07 | −2.98 | −0.5 | 5 | −1.4 | 74.44 | −4.8 | −2 | - |
| 61 | 298.37 | - | 4.88 | 542.6 | 3 | 7.1 | 1.06 | −2.98 | −0.5 | 5 | −1.4 | 74.36 | −4.79 | −2 | - |
| 62 | 366.92 | 3 | 3.08 | 712.65 | - | 2 | 6.67 | −8.41 | 1.37 | 5 | 0.21 | 100 | −6.17 | 1 | 1 |
| 63 | 432.59 | 4 | 5.23 | 855.53 | - | 4 | 7 | −9.13 | 1.52 | 6 | −0.86 | 100 | −6.63 | −1 | 2 |
| 64 | 282.8 | 1 | 5.1 | 546.49 | 1 | 1.7 | 4.64 | −5.5 | 0.57 | 4 | 0.34 | 100 | −5.39 | 1 | - |
| 65 | 348.47 | - | 4.77 | 685.58 | 1 | 3.7 | 4.9 | −6.42 | 0.76 | 5 | −0.85 | 100 | −5.81 | −1 | 1 |
| 66 | 348.47 | 1 | 5.79 | 721.29 | 1 | 3.7 | 5.08 | −7.07 | 0.82 | 6 | −0.93 | 100 | −6.37 | −1 | 1 |
| 67 | 678.93 | 10 | 5.34 | 1180.96 | - | 5.7 | 10.73 | −13.34 | 2.73 | 11 | −1.63 | 100 | −8.35 | −2 | 2 |
| 68 | 492.68 | 5 | 2.25 | 916.97 | - | 3.4 | 9.48 | −11.13 | 2.07 | 8 | −0.68 | 100 | −8.28 | - | 1 |
| 69 | 492.68 | 5 | 2.32 | 856.86 | - | 3.4 | 8.46 | −10.47 | 1.88 | 8 | −0.68 | 100 | −7.68 | - | 1 |
| 70 | 492.68 | 6 | 1.67 | 848.1 | - | 3.4 | 8.4 | −10.35 | 1.93 | 10 | −0.68 | 100 | −7.54 | - | - |
| 71 | 364.47 | - | 4.17 | 731.03 | 2 | 5.4 | 3.97 | −6.33 | 0.43 | 6 | −1.58 | 95.78 | −6.38 | −2 | 1 |
| 72 | 262.34 | 1 | 4.69 | 537.04 | 1 | 3.7 | 2.72 | −4.24 | 0.05 | 4 | −0.92 | 91.26 | −5.42 | −1 | - |
| 73 | 246.34 | 1 | 2.19 | 521.45 | 1 | 1.7 | 3.88 | −4.78 | 0.38 | 3 | −0.03 | 100 | −5.63 | - | - |
| 74 | 264.36 | - | 2.47 | 545.82 | 2 | 3.4 | 2.92 | −4.18 | 0.02 | 5 | −0.73 | 96.95 | −5.5 | −1 | - |
| 75 | 248.38 | 6 | 0.96 | 464.31 | - | - | 5.71 | −7.4 | 0.83 | 3 | 0.19 | 100 | −5.33 | 1 | - |
| 76 | 276.39 | 1 | 4.61 | 502.07 | - | 2 | 3.95 | −4.98 | 0.46 | 3 | 0.03 | 100 | −5.34 | 1 | - |
| 77 | 278.4 | 1 | 2.58 | 511.2 | 1 | 1.7 | 4.22 | −5.06 | 0.5 | 4 | 0.2 | 100 | −5.44 | 1 | - |
| 78 | 278.4 | 3 | 1.84 | 505.75 | - | 0.75 | 5.62 | −5.96 | 0.83 | 4 | 0.03 | 100 | −5.34 | 1 | - |
| 79 | 360.5 | 1 | 2.73 | 671.68 | - | 2 | 6.27 | −7.84 | 1.29 | 6 | 0.18 | 100 | −6.45 | 1 | 1 |
| 80 | 360.5 | 1 | 3.82 | 678.33 | - | 2 | 6.24 | −7.98 | 1.3 | 6 | 0.08 | 100 | −6.53 | 1 | 1 |
| 81 | 292.43 | 2 | 2.1 | 542.23 | - | 1.7 | 5.44 | −5.81 | 0.72 | 5 | −0.31 | 100 | −5.61 | - | - |
| 82 | 426.52 | - | 3.15 | 644.26 | 4 | 9.25 | 2.04 | −4.08 | −0.27 | 7 | −1.16 | 83.97 | −5.71 | −2 | 1 |
| 82 | 426.52 | - | 3.4 | 642.05 | 4 | 9.25 | 2.03 | −4.08 | −0.26 | 7 | −1.21 | 82.47 | −5.59 | −2 | 1 |
| 82 | 426.52 | - | 4.89 | 649.11 | 4 | 9.25 | 2.05 | −4.16 | −0.26 | 7 | −1.21 | 83.16 | −5.76 | −2 | 1 |
| 82 | 426.52 | - | 2.93 | 642.67 | 4 | 9.25 | 2.16 | −4.08 | −0.27 | 7 | −0.99 | 87.19 | −5.61 | −1 | 1 |
| 83 | 540.79 | 6 | 4.22 | 945.88 | - | 2 | 9.78 | −12.95 | 2.68 | 6 | −0.12 | 100 | −8.05 | - | - |
| 84 | 197.25 | - | 6.72 | 419.53 | 1 | 4.7 | 1.09 | −2.13 | −0.51 | 4 | −0.42 | 86.7 | −3.64 | - | - |
| 85 | 316.37 | 1 | 3.62 | 593.36 | 2 | 5.45 | 2.42 | −4.27 | 0.05 | 6 | −1.29 | 85.52 | −5.02 | −2 | 1 |
| 86 | 280.38 | - | 4.82 | 549.83 | 1 | 5.4 | 2.64 | −3.42 | −0.09 | 5 | −0.73 | 95.86 | −4.44 | −1 | - |
| 86 | 280.38 | - | 6.54 | 568.11 | 1 | 4.45 | 3.19 | −4.05 | 0.12 | 4 | −0.68 | 100 | −4.85 | - | - |
| 86 | 280.38 | - | 6.55 | 555.35 | 1 | 4.45 | 3.06 | −3.82 | 0.08 | 4 | −0.71 | 100 | −4.68 | −1 | - |
| 86 | 280.38 | - | 5.66 | 564.44 | 1 | 4.45 | 3.08 | −4.01 | 0.09 | 4 | −0.75 | 100 | −4.83 | −1 | - |
| 86 | 280.38 | - | 4.24 | 564.71 | 1 | 4.45 | 3.08 | −3.98 | 0.11 | 4 | −0.79 | 100 | −4.78 | −1 | - |
| 87 | 350.41 | - | 9.97 | 600.63 | 1.25 | 6.25 | 3.04 | −4.55 | −0.14 | 3 | −1.21 | 76.31 | −3.41 | −2 | 1 |
| 87 | 350.41 | - | 3.36 | 593.33 | 1.25 | 6.25 | 2.95 | −4.37 | −0.14 | 3 | −1.23 | 75.36 | −3.25 | −2 | 1 |
| 87 | 350.41 | - | 7.76 | 582.94 | 1.25 | 6.25 | 2.99 | −4.17 | −0.17 | 3 | −1.04 | 78.73 | −3.14 | −2 | 1 |
| 87 | 350.41 | - | 8.61 | 596.55 | 1.25 | 6.25 | 3.04 | −4.47 | −0.14 | 3 | −1.18 | 76.64 | −3.33 | −2 | 1 |
| 88 | 432.58 | 2 | 2.52 | 761.06 | 1 | 3.75 | 6.09 | −7.38 | 1.59 | 3 | 0.48 | 100 | −6.96 | 2 | - |
| 88 | 432.58 | 2 | 2.52 | 761.06 | 1 | 3.75 | 6.09 | −7.38 | 1.59 | 3 | 0.48 | 100 | −6.96 | 2 | - |
| 89 | 332.41 | - | 3.73 | 648.07 | - | 4.75 | 4.13 | −5.57 | 0.45 | 3 | −0.34 | 100 | −5.16 | - | - |
| 90 | 376.42 | - | 5.82 | 693.39 | 1 | 6.75 | 3.51 | −5.75 | 0.2 | 3 | −1.6 | 76.93 | −3.34 | −2 | - |
| 91 | 348.41 | - | 2.67 | 673.35 | 1 | 6.45 | 3.34 | −5.55 | 0.28 | 3 | −0.88 | 100 | −5.43 | −1 | - |
| 92 | 348.41 | - | 5.79 | 664.93 | 1 | 6.45 | 3.2 | −5.39 | 0.28 | 3 | −1.03 | 94.16 | −5.22 | −2 | - |
| 93 | 350.43 | - | 2.82 | 679.38 | 1 | 6.45 | 3.41 | −5.5 | 0.28 | 4 | −0.95 | 100 | −5.29 | −1 | - |
| 94 | 350.43 | - | 4.86 | 665.38 | 1 | 6.45 | 3.35 | −5.25 | 0.26 | 4 | −0.91 | 100 | −5.09 | −1 | - |
| 95 | 234.31 | - | 6.4 | 449.04 | - | 3.7 | 2.41 | −2.95 | −0.18 | 5 | 0.28 | 100 | −3.85 | 1 | - |
| 95 | 234.31 | - | 6.3 | 424.55 | - | 2.75 | 2.8 | −3 | 0.03 | 3 | 0.3 | 100 | −3.42 | 1 | - |
| 95 | 234.31 | - | 6.52 | 444.21 | - | 2.75 | 2.96 | −3.37 | 0.1 | 3 | 0.26 | 100 | −3.77 | 1 | - |
| 95 | 234.31 | - | 6.52 | 444.21 | - | 2.75 | 2.96 | −3.37 | 0.1 | 3 | 0.26 | 100 | −3.77 | 1 | - |
| 95 | 234.31 | - | 6.3 | 424.54 | - | 2.75 | 2.8 | −3 | 0.03 | 3 | 0.3 | 100 | −3.42 | 1 | - |
| 96 | 294.37 | - | 6.75 | 555.68 | 1 | 5.7 | 2.37 | −3.57 | −0.1 | 5 | −0.9 | 90.35 | −4.57 | −1 | 1 |
| 96 | 294.37 | - | 4.21 | 564.47 | 1 | 6.2 | 2.14 | −3.54 | −0.17 | 4 | −1.09 | 85.98 | −4.81 | −2 | 1 |
| 96 | 294.37 | - | 8.99 | 556.37 | 1 | 6.2 | 2.17 | −3.43 | −0.18 | 4 | −0.96 | 87.87 | −4.63 | −1 | 1 |
| 96 | 294.37 | - | 4.8 | 551.9 | 1 | 6.2 | 2.08 | −3.35 | −0.2 | 4 | −1.03 | 86.02 | −4.63 | −2 | 1 |
| 96 | 294.37 | - | 7.82 | 549 | 1 | 6.2 | 2.16 | −3.29 | −0.22 | 4 | −0.88 | 89.33 | −4.65 | −1 | 1 |
# Stars: Number of property or descriptor values that fall outside the 95% range of similar values for known drugs. Many stars suggest that a molecule is less drug-like than molecules with few stars; Dipole: Computed dipole moment of the molecule; SASA: Total solvent accessible surface area (SASA) in square angstroms using a probe with a 1.4 Å radius; Donor H-bond: Estimated number of hydrogen bonds that the solute would donate to water molecules in an aqueous solution; Acceptor H-bond: Estimated number of hydrogen bonds that the solute would accept from water molecules in an aqueous solution; QPlogPo/w: Predicted octanol/water partition coefficient.; QPlogS: Predicted aqueous solubility, log S; QPlogkhsa: Prediction of binding to human serum albumin; # Metab: Number of likely metabolic reactions.; QplogBB: Predicted brain/blood partition coefficient; % Human Oral Absorption: Predicted human oral absorption on 0 to 100% scale; QPlogHERG: Predicted IC50 value for blockage of HERG K+ channels; CNS: Predicted central nervous system activity on a −2 (inactive) to +2 (active) scale; # rtvFG: Number of reactive functional groups; the specific groups are listed in the jobname out file. The presence of these groups can lead to false positives in HTS assays and to decomposition, reactivity, or toxicity problems in vivo.
Figure 12N-(3,4-dimethoxybenzyl)-Nalpha-{N-[(3,4-dimethoxyphenyl)acetyl] carbamimidoyl}-D-phenylalaninamide (2RZ) complexed with Cathepsin D PDB: 4OD9 after preparation, using Protein Preparation Wizard, from Schrodinger, where hydrogen bonds are optimized, and the whole complex minimized and represented as a 3D structure.
In silico screening results of thiophene derivatives against Cathepsin D (PDB: 4OD9).
| Compd | Docking Score | XP GScore | Glide GScore | Glide Emodel |
|---|---|---|---|---|
| 29 | −9.439 | −9.439 | −9.439 | −62.9 |
| 30 | −9.178 | −9.178 | −9.178 | −61.357 |
| 82 | −8.09 | −8.09 | −8.09 | −64.014 |
| 42 | −6.971 | −6.971 | −6.971 | −45.831 |
| Ref_4OD9 | −6.895 | −7.306 | −7.306 | −71.557 |
| 66 | −6.889 | −6.889 | −6.889 | −56.795 |
| 64 | −6.772 | −6.772 | −6.772 | −47.815 |
| 61 | −6.677 | −6.677 | −6.677 | −45.925 |
| 39 | −6.567 | −6.567 | −6.567 | −68.455 |
| 40 | −6.567 | −6.567 | −6.567 | −68.455 |
| 57 | −6.484 | −6.484 | −6.484 | −44.895 |
| 33 | −6.478 | −6.478 | −6.478 | −37.519 |
| 46 | −6.385 | −6.385 | −6.385 | −54.121 |
| 19 | −6.374 | −6.374 | −6.374 | −39.754 |
| 81 | −6.373 | −6.373 | −6.373 | −40.88 |
| 92 | −6.297 | −6.297 | −6.297 | −50.1 |
| 9 | −6.119 | −6.119 | −6.119 | −37.184 |
| 52 | −6.056 | −6.056 | −6.056 | −39.105 |
| 2 | −5.946 | −5.946 | −5.946 | −35.558 |
| 89 | −5.913 | −5.913 | −5.913 | −41.976 |
| 68 | −5.91 | −5.91 | −5.91 | −58.146 |
| 59 | −5.879 | −5.879 | −5.879 | −43.627 |
| 58 | −5.789 | −5.789 | −5.789 | −39.479 |
| 41 | −5.775 | −5.778 | −5.778 | −50.687 |
| 84 | −5.761 | −5.761 | −5.761 | −35.037 |
| 31 | −5.624 | −5.624 | −5.624 | −39.484 |
| 17 | −5.589 | −5.589 | −5.589 | −58.566 |
| 91 | −5.563 | −5.563 | −5.563 | −39.688 |
| 65 | −5.534 | −5.534 | −5.534 | −52.028 |
| 74 | −5.522 | −5.522 | −5.522 | −50.032 |
| 49 | −5.439 | −5.439 | −5.439 | −37.501 |
| 53 | −5.431 | −5.431 | −5.431 | −42.062 |
| 60 | −5.413 | −5.413 | −5.413 | −48.483 |
| 32 | −5.359 | −5.359 | −5.359 | −36.918 |
| 37 | −5.344 | −5.344 | −5.344 | −38.255 |
| 95 | −5.323 | −5.733 | −5.733 | −31.554 |
| 12 | −5.317 | −5.32 | −5.32 | −48.638 |
| 93 | −5.294 | −5.294 | −5.294 | −41.169 |
| 71 | −5.234 | −5.234 | −5.234 | −56.25 |
| 77 | −5.182 | −5.182 | −5.182 | −47.296 |
| 80 | −5.175 | −5.175 | −5.175 | −52.89 |
| 20 | −5.032 | −5.032 | −5.032 | −38.495 |
| 47 | −4.988 | −4.988 | −4.988 | −41.313 |
| 48 | −4.959 | −4.959 | −4.959 | −45.598 |
| 79 | −4.959 | −4.959 | −4.959 | −53.558 |
| 87 | −4.892 | −4.892 | −4.892 | −42.972 |
| 70 | −4.788 | −4.788 | −4.788 | −66.838 |
| 16 | −4.761 | −4.761 | −4.761 | −39.898 |
| 22 | −4.708 | −4.708 | −4.708 | −43.587 |
| 76 | −4.681 | −4.681 | −4.681 | −42.185 |
| 50 | −4.616 | −4.616 | −4.616 | −42.266 |
| 62 | −4.615 | −4.615 | −4.615 | −53.205 |
| 38 | −4.587 | −4.587 | −4.587 | −44.277 |
| 21 | −4.479 | −4.479 | −4.479 | −34.302 |
| 96 | −4.434 | −4.844 | −4.844 | −43.679 |
| 27 | −4.427 | −4.427 | −4.427 | −32.461 |
| 54 | −4.4 | −4.4 | −4.4 | −42.328 |
| 36 | −4.372 | −4.372 | −4.372 | −31.206 |
| 34 | −4.367 | −4.367 | −4.367 | −32.958 |
| 10 | −4.36 | −4.36 | −4.36 | −37.183 |
| 4 | −4.325 | −4.325 | −4.325 | −44.054 |
| 55 | −4.289 | −4.289 | −4.289 | −41.301 |
| 86 | −4.263 | −4.673 | −4.673 | −34.699 |
| 67 | −4.242 | −4.242 | −4.242 | −71.461 |
| 72 | −4.221 | −4.221 | −4.221 | −45.333 |
| 56 | −4.166 | −4.166 | −4.166 | −45.866 |
| 18 | −4.159 | −4.159 | −4.159 | −38.902 |
| 28 | −4.131 | −4.131 | −4.131 | −38.886 |
| 51 | −4.127 | −4.127 | −4.127 | −38.518 |
| 73 | −4.109 | −4.109 | −4.109 | −41.377 |
| 88 | −4.09 | −4.09 | −4.09 | −46.666 |
| 94 | −4.085 | −4.085 | −4.085 | −40.186 |
| 35 | −4.079 | −4.079 | −4.079 | −30.767 |
| 44 | −4.047 | −4.047 | −4.047 | −41.625 |
| 75 | −4.012 | −4.012 | −4.012 | −39.751 |
| 69 | −3.964 | −3.964 | −3.964 | −65.916 |
| 85 | −3.899 | −3.899 | −3.899 | −35.518 |
| 83 | −3.778 | −3.778 | −3.778 | −63.675 |
| 13 | −3.769 | −3.769 | −3.769 | −38.792 |
| 9 | −3.688 | −3.688 | −3.688 | −41.071 |
| 23 | −3.688 | −3.688 | −3.688 | −41.071 |
| 14 | −3.65 | −3.65 | −3.65 | −38.638 |
| 11 | −3.64 | −3.64 | −3.64 | −42.16 |
| 43 | −3.528 | −3.528 | −3.528 | −37.644 |
| 25 | −3.481 | −3.481 | −3.481 | −39.665 |
| 24 | −3.48 | −3.483 | −3.483 | −44.761 |
| 78 | −3.406 | −3.406 | −3.406 | −37.385 |
| 45 | −3.403 | −3.403 | −3.403 | −30.006 |
| 3 | −3.303 | −3.303 | −3.303 | −26.546 |
| 15 | −3.253 | −3.253 | −3.253 | −35.921 |
| 90 | −3.239 | −3.239 | −3.239 | −43.733 |
| 26 | −3.185 | −3.185 | −3.185 | −40.847 |
| 8 | −2.058 | −2.117 | −2.117 | −23.999 |
| 63 | −1.85 | −1.85 | −1.85 | −70.342 |
| 7 | −1.55 | −1.55 | −1.55 | −18.635 |
| 5 | −0.841 | −0.841 | −0.841 | −10.861 |
Figure 13Cathepsin D in complex with 29 represented as 3D molecular surface and ribbon structure.
Figure 14(A) Putative binding mode of 29 in the binding site of cathepsin PDB: 4OD9. Compound 29 is displayed as green sticks. The amino acids residues of the binding site are represented as grey sticks, and H-bonds are represented in yellow dotted, (B) 2D depiction of the ligand–protein interactions.
Figure 15(A) Putative binding mode of compound 30 in the binding site of Cathepsin PDB: 4OD9. Compound 30 is displayed as green sticks. The amino acids residues of the binding site are represented as grey sticks, and H-bonds are represented in yellow dotted, (B) 2D depiction of the ligand–protein interactions.
Figure 16(A) Putative binding mode of Reference in the binding site of Cathepsin PDB: 4OD9. The green sticks represent the Reference, whereas the grey sticks represent amino acid residues, and the yellow dotted lines represent the H-bond. (B) 2D depiction of the ligand–protein interactions.
Figure 17RMSD analysis for compound 30 complexed with cathepsin D (PDB Code) of MD simulation trajectory. The RMSD plot was obtained for compound 30 complexed with cathepsin D (PDB ID 4OD9). The 100 ns simulation time reaffirms the stability of the complex without any significant changes in the structure.
Figure 18Cathepsin D interactions with compound 30 throughout the simulation. The interactions between the ligand and protein are classified into hydrophobic, ionic, hydrogen bond, and water bridges. Each classification can be further sub-grouped and observed in the ‘Simulation Interactions Diagram’ panel. The stacked bar charts are normalized throughout the trajectory. The stacked bar charts are normalized over the course of the trajectory: for example, a value of 0.7 suggests that 70% of the simulation time, the specific interaction is maintained. Values over 1.0 are possible, as some protein residue may make multiple contacts of the same subtype with the ligand.
Figure 19The schematic diagram shows the detailed atomic interaction of compound 30 with Cathepsin D. Interactions that occur more than 30.0% of the simulation time in the selected trajectory (0.00 through 100.00 ns). It is possible to have interactions with >100% as some residues may have multiple interactions of a single type with the same ligand atom.
Figure 20Summary of the reported structure–activity relationship (SAR) of thiophenes. ↑: increase; ↓: decrease [19,32,34,41].